A randomized controlled trial (RCT) conducted by Kim et al. on albuminuria in patients with type 2 diabetes concluded that lobeglitazone improved albuminuria in patients with type 2 diabetes as measured by the urinary albumin-creatinine ratio (UACR), and demonstrated it as beneficial. The gene discussed is ALB; the disease is type 2 diabetes mellitus.